var data={"title":"Belinostat: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Belinostat: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/743370?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=belinostat-patient-drug-information\" class=\"drug drug_patient\">see &quot;Belinostat: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25330728\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Beleodaq</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25243926\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Histone Deacetylase (HDAC) Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319638\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> ANC should be &ge;1,000/mm<sup>3</sup> and platelets should be &ge;50,000/mm<sup>3</sup> prior to each cycle</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral T-cell lymphoma, relapsed or refractory:</b> IV: 1,000 mg/m<sup>2</sup> daily on days 1 to 5 every 21 days until disease progression or unacceptable toxicity (O&rsquo;Connor 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Dosage adjustment for patients with reduced UGT1A1 activity:</i> Reduce initial dose to 750 mg/m<sup>2</sup> for patients known to be homozygous for UGT1A1*28 allele.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319639\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319698\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &gt;39 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling. However, exposure is not altered; dosage adjustment is not likely necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &le;39 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (data is insufficient to recommend a dose).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319699\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild hepatic impairment: There are no dosage adjustments provided in the manufacturer's labeling (exposure is expected to be increased in hepatic impairment).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate to severe hepatic impairment (total bilirubin &gt;1.5 times ULN): There are no dosage adjustments provided in the manufacturer's labeling (data is insufficient to recommend a dose).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319700\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer:</i> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319701\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematologic toxicity: </b>ANC should be &ge;1000/mm<sup>3</sup> and platelets should be &ge;50,000/mm<sup>3</sup> prior to each cycle and prior to resuming treatment following a delay due to toxicity. Resume subsequent treatment according to the following parameters:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets &ge;25,000/mm<sup>3</sup> and nadir ANC &ge;500/mm<sup>3</sup>: No dosage adjustment necessary (continue treatment without modification).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nadir ANC &lt;500/mm<sup>3</sup> and any platelet count: Reduce dose to 75% of the usual dose (to 750 mg/m<sup>2</sup>).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets &lt;25,000/mm<sup>3</sup> and any nadir ANC: Reduce dose to 75% of the usual dose (to 750 mg/m<sup>2</sup>).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recurrent nadir ANC &lt;500/mm<sup>3</sup> and/or recurrent nadir platelets &lt;25,000/mm<sup>3</sup> following 2 dosage reductions: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonhematologic toxicity:</b> Nonhematologic toxicities should be grade 2 or lower prior to retreatment. Resume subsequent treatment according to the following parameters:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Any grade 3 or 4 toxicity (except nausea, vomiting, or diarrhea): Reduce dose to 75% of the usual dose (to 750 mg/m<sup>2</sup>).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recurrent grade 3 or 4 toxicity following 2 dosage reductions: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 or 4 nausea, vomiting, or diarrhea: Manage with supportive care; reduce the dose only if duration is &gt;7 days with supportive management.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25330729\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Beleodaq: 500 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25330727\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319704\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse over 30 minutes using a 0.22-micron inline filter; if infusion site pain or other symptoms associated with infusion occur, may increase infusion time to 45 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130896\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25243928\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Peripheral T-cell lymphoma, relapsed or refractory:</b> Treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319423\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Belinostat may be confused with belatacept, belimumab, vorinostat</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25320124\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (20%), prolonged Q-T interval on ECG (11%; grades 3/4: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (37%; grades 3/4: 5%), chills (16%; grades 3/4: 1%), headache (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (20%; grades 3/4: 1%), pruritus (16%; grades 3/4: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased lactate dehydrogenase (16%; grades 3/4: 2%), hypokalemia (12%; grades 3/4: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (42%; grades 3/4: 1%), vomiting (29%; grades 3/4: 1%), constipation (23%; grades 3/4: 1%), diarrhea (23%; grades 3/4: 2%), decreased appetite (15%; grades 3/4: 2%), abdominal pain (11%; grades 3/4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (32%; grades 3/4: 11%), thrombocytopenia (16%; grades 3/4: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (22%; grades 3/4: 6%), cough (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (35%; grades 3/4: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (10%; grades 3/4: 3%), phlebitis (10%; grades 3/4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (&gt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (&gt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pneumonia (&gt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Multi-organ failure (&gt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, febrile neutropenia, hepatic failure, hepatotoxicity, leukopenia, sepsis, tumor lysis syndrome, ventricular fibrillation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25243958\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319430\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: May cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia. Monitor blood counts at baseline and weekly during treatment. May require dosage reduction, treatment delay, or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Nausea, vomiting, and diarrhea occur with belinostat; may require management with antiemetic and antidiarrheal medications. In a phase 1 study, nausea/vomiting generally occurred at the end of the infusion each day (rarely persisting beyond day 5 each cycle) and was managed with standard antiemetics (Steele 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: May cause liver function test abnormalities and fatal hepatotoxicity. Monitor liver function tests at baseline and prior to each cycle. May require dosage reduction, treatment delay, or permanent discontinuation (based on the severity of the hepatotoxicity). Belinostat is metabolized hepatically and increased exposure is expected to occur in patients with hepatic impairment. Patients with moderate to severe hepatic impairment (total bilirubin &gt;1.5 times ULN) were excluded from clinical studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Serious infections (occasionally fatal), including pneumonia and sepsis, have occurred with treatment. Do not administer in patients with an active infection. Heavily pretreated patients (history of extensive or intensive prior chemotherapy) may be at higher risk for life-threatening infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome (TLS) has been observed; closely monitor patients with advanced disease and/or high tumor burden. If TLS occurs, initiate appropriate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reduced UGT1A1 activity: Belinostat is primarily metabolized by UGT1A1; the initial dose should be reduced in patients known to be homozygous for UGT1A1*28 allele.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25331892\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (minor), CYP2C9 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1, UGT1A1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25331889\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=96188&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: May increase the serum concentration of Belinostat.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319426\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319427\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Belinostat is a genotoxic drug that targets dividing cells; embryofetal toxicity is expected if exposure occurs during pregnancy. Based on animal data, belinostat may also impair male fertility. Women of reproductive potential should avoid pregnancy during treatment with belinostat.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319429\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if belinostat is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends that a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319706\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor CBC with platelets and differential at baseline and weekly; serum chemistries (including renal and hepatic functions tests) at baseline and before each cycle; monitor for signs/symptoms of gastrointestinal toxicity (eg, nausea, vomiting, diarrhea), tumor lysis syndrome, and infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319542\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Belinostat is a histone deacetylase (HDAC) inhibitor which catalyzes acetyl group removal from protein lysine residues (of histone and some nonhistone proteins). Inhibition of histone deacetylase results in accumulation of acetyl groups, leading to cell cycle arrest and apoptosis. Belinostat has preferential cytotoxicity toward tumor cells versus normal cells.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25319563\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: ~114 L/m<sup>2</sup> (Steele 2011); mean volume of distribution approaches total body water</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~93% to 96%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; predominantly via UGT1A1, also by CYP2A6, CYP2C9, and CYP3A4 to the amide and acid metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 1.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: At end of infusion (Steele 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (84.8% &plusmn; 9.8% over 168 hours, predominantly as metabolites; &lt;2% as unchanged drug); feces (9.7% &plusmn; 6.5% over 168 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25745804\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Beleodaq Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $2,131.56</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Beleodaq (belinostat) [prescribing information]. Irvine, CA; Spectrum Pharmaceuticals: April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al; American Society of Clinical Oncology. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2012;30(13):1553-1561.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/belinostat-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Connor OA, Masszi T, Savage KJ, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial [Abstract 8507 from 2013 ASCO annual meeting]. <i>J Clin Oncol</i>. 2013;31(15s):8507.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steele NL, Plumb JA, Vidal L, et al. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). <i>Cancer Chemother Pharmacol</i>. 2011;67(6):1273-1279.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/belinostat-drug-information/abstract-text/20706839/pubmed\" target=\"_blank\" id=\"20706839\">20706839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 96188 Version 55.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F25330728\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F25243926\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F25319638\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F25319639\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F25319698\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F25319699\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F25319700\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F25319701\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F25330729\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F25330727\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F25319704\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130896\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F25243928\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25319423\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F25320124\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F25243958\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F25319430\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F25331892\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F25331889\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F25319426\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F25319427\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F25319429\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F25319706\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F25319542\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F25319563\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F25745804\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/96188|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=belinostat-patient-drug-information\" class=\"drug drug_patient\">Belinostat: Patient drug information</a></li></ul></div></div>","javascript":null}